Incannex Healthcare Limited
IXHL
Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's products include IHL-42X, which is in Phase II clinical trials for obstructive sleep apnea; IHL-216A for traumatic brain injury; and IHL-675A, a combination of hydroxychloroquine aā¦ read more
Healthcare
Drug ManufacturersāSpecialty & Generic
3 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$0.40
Price+2.31%
$0.01
1Y
Price
Market Cap
$13.713m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-58617.0%
EBITDA Margin-53395.4%
Net Profit Margin-1550.6%
Free Cash Flow Margin-58617.0%
EBITDA Margin-53395.4%
Net Profit Margin-1550.6%
Free Cash Flow MarginRevenue
$86k
+985.1%
1y CAGR+328.4%
3y CAGR+221.3%
5y CAGREarnings
-$46.885m
-116.0%
1y CAGR-149.6%
3y CAGR-117.2%
5y CAGREPS
-$1.36
-62.3%
1y CAGR-3488.3%
3y CAGR-2616.2%
5y CAGRBook Value
$13.389m
$20.447m
Assets$7.058m
Liabilities$258k
DebtDebt to Assets
1.3%
-
Debt to EBITDAFree Cash Flow
-$12.521m
+8.7%
1y CAGR-20.7%
3y CAGR-33.2%
5y CAGRNo items found.
Press Releases
Statements and updates from the company